Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd (Stock ID: 852453) surged to its upper circuit limit on 19 Mar 2026, closing at ₹120.5, marking a maximum daily gain of 4.99%. This sharp rally was driven by robust buying interest, with the stock outperforming its sector and broader market indices despite a subdued market environment.

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 18 Mar 2026, reflecting robust buying interest and a maximum daily gain of 4.99%. The micro-cap pharmaceutical stock outperformed its sector and broader market indices, signalling renewed investor enthusiasm despite its Strong Sell mojo grade.

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 17 Mar 2026, reflecting robust investor demand and significant buying momentum. The stock closed at ₹109.31, marking a maximum daily gain of 4.99%, outperforming its sector and broader market indices amid heightened trading activity and regulatory freeze on further price movement.

Bafna Pharmaceuticals Ltd surged to hit its upper circuit limit on 16 Mar 2026, registering a maximum daily gain of 4.99% to close at ₹104.11. This sharp rally was driven by robust buying interest despite the stock opening with a gap down, signalling a notable reversal after three consecutive days of decline in a challenging micro-cap pharmaceuticals sector.

Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 March 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company faces significant challenges across quality, valuation, financial trends, and technical parameters that have prompted a reassessment of its investment appeal.

Bafna Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s long-term strength amid ongoing sector challenges.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shares of Bafna Pharmaceuticals Ltd plunged to their lower circuit limit on 9 Mar 2026, closing at ₹106.59, marking a maximum daily loss of 4.99%. The stock witnessed intense selling pressure, with volumes concentrated near the day’s low, signalling panic selling and unfilled supply in the micro-cap pharmaceutical firm.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 28 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Bafna Pharmaceuticals Ltd., a Chennai-based pharmaceutical formulations manufacturer, has posted concerning profitability trends in Q3 FY26, with net profit declining 30.40% sequentially to ₹1.84 crores despite relatively stable revenue performance. The micro-cap pharmaceutical company, with a market capitalisation of ₹308.00 crores, has seen its shares retreat 16.24% year-to-date to ₹130.00, reflecting growing investor scepticism about the sustainability of its recent turnaround efforts.

Bafna Pharmaceuticals Ltd surged to its upper circuit limit on 10 Feb 2026, registering a maximum daily gain of 4.97% and closing at ₹127.85. The stock’s robust performance was driven by intense buying interest, resulting in a regulatory freeze on further trading and highlighting unfilled demand in the market.

Bafna Pharmaceuticals Ltd (BE: 852453) surged to its upper circuit limit on 09 Feb 2026, closing at ₹121.8, marking a maximum daily gain of 5.0%. The stock demonstrated robust buying interest, outperforming its sector and broader market indices despite a backdrop of falling investor participation and regulatory trading restrictions.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.